Latest Conference Articles

Highlighting conditions like lichen planus, which has no FDA-approved treatments, Lio underscores why clinicians must be comfortable prescribing beyond the label.

The 2026 meeting emphasized integrating cutting-edge medical therapies with aesthetic strategies to address both disease control and quality of life.

Advances in stem cells, exosomes, biomaterials, and RNA technologies are expanding therapeutic options beyond traditional wound-based remodeling.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

Modern hidradenitis suppurativa (HS) management prioritizes restoration of function and quality of life, not just reduction in lesion counts, according to Barry Resnik, MD.

Clinicians are increasingly facing barriers when attempting to prescribe on-label treatments for indicated patients.

Catch up on coverage from the third day of South Beach Symposium 2026.

GLP-1 therapies represent a paradigm shift requiring dermatology to integrate metabolic, medical, and aesthetic care.

At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.

At MOPD 2026, Lisa Swanson, MD, urges fungal cultures amid terbinafine resistance and warns attendees about risky kids’ skin care trends.

At South Beach Symposium 2026, Benjamin Ungar, MD, discussed safer, long-term approaches for seborrheic dermatitis.

Catch up on coverage from the second day of South Beach Symposium 2026.

Glynis Ablon, MD, FAAD, shares insights on diagnosing alopecia fast, managing aesthetic complications, and choosing evidence-based supplements.

Antonio Torrelo, MD, emphasizes that genetic testing enhances—but never replaces—clinical judgment in pediatric dermatology.

Doris Day, MD, reframes anti-aging: support fibroblasts, longevity pathways, lifestyle and smart fillers for healthier skin quality.

At SBS 2026, Karan Lal, MD, and Mohammad Goldust, MD, reveal how social media and AI reshape dermatology trust and care.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

Catch up on coverage from the first day of South Beach Symposium 2026.

At MOPD 2026, Kristina Derrick, MD, ScM, links teen acne to hormones and metabolism, highlighting PCOS clues and antiandrogen therapies.

Michael Gold, MD, shares insights on safer device use, peptides, GLP-1s, acne, hair therapies, and more.

MOPD 2026 brings together leading experts to review recent therapeutic advances and practical management strategies in pediatric dermatology.

As SBS kicks off in South Beach Miami, scroll through faces familiar to Dermatology Times presenting at the symposium.

UCB shares 3-year BIMZELX (bimekizumab) data in HS, showing sustained hidradenitis suppurativa lesion clearance and major severity reductions.

Catch up on the latest research posters presented at last month's conferences, compiled all in one place for dermatology professionals.

Explore top dermatology conferences and meetings in February 2026 and let us know which ones you'll be attending!

Icotrokinra emerges as a groundbreaking oral treatment for moderate to severe psoriasis, showing superior efficacy compared with existing therapies at Maui Derm 2026.

Galderma addresses menopause-related skin changes at IMCAS 2026, revealing survey insights and committing to inclusive clinical trials for better patient solutions.

Discover insights from Bill Andriopoulos, PhD, on Relfydess, a groundbreaking neuromodulator utilizing PEARL Technology for enhanced efficacy and safety.